Gajewska Joanna, Chełchowska Magdalena, Rychłowska-Pruszyńska Magdalena, Klepacka Teresa, Ambroszkiewicz Jadwiga
Department of Screening Tests and Metabolic Diagnostics, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland.
Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland.
J Clin Med. 2022 Mar 17;11(6):1663. doi: 10.3390/jcm11061663.
Aims. There are no data on the redox status of children with bone tumors in complete disease remission. Therefore, the presented study examined the reduced/oxidized glutathione (GSH/GSSG) ratio, total oxidant capacity (TOC) and total antioxidant capacity (TAC) values as well as the oxidative stress index (OSI) for assessing alterations in the oxidant/antioxidant balance in 35 children with osteosarcoma or Ewing’s sarcoma after anticancer therapy completion (median 14 months) compared with a control group. Methods. GSH, GSSG, TOC, TAC concentrations and bone alkaline phosphatase (BALP) activity were evaluated by immunoenzymatic (ELISA) and enzymatic methods. Results. We found no differences in serum BALP activity between all survivors with bone tumors and the control group. Patients with osteosarcoma after anticancer therapy completion had significantly higher values of TAC, GSH and the GSH/GSSG ratio as well as GSSG than healthy subjects. In patients with Ewing’s sarcoma, we found significantly higher values of TOC concentration compared with healthy children. In addition, survivors with Ewing’s sarcoma had higher TOC concentrations and OSI index values (p < 0.01), but a lower GSH/GSSG ratio (p < 0.05) than survivors with osteosarcoma. A positive correlation between TOC and the post-therapy period was observed in survivors. Conclusions. We found that in survivors with bone tumors, a disturbed balance between prooxidants and antioxidants persists after the completion of anticancer treatment. Moreover, an increased TOC value together with the post-therapy period may suggest increasing oxidative processes in survivors with bone tumors after treatment. Further observations will allow assessment of the relationship between the oxidant/antioxidant status and the predisposition of survivors to bone neoplastic disease recurrence.
目的。目前尚无关于骨肿瘤患儿疾病完全缓解时氧化还原状态的数据。因此，本研究检测了35例骨肉瘤或尤文肉瘤患儿在完成抗癌治疗后（中位时间14个月）的还原型/氧化型谷胱甘肽（GSH/GSSG）比值、总氧化能力（TOC）、总抗氧化能力（TAC）值以及氧化应激指数（OSI），以评估氧化剂/抗氧化剂平衡的变化，并与对照组进行比较。方法。采用免疫酶法（ELISA）和酶法评估GSH、GSSG、TOC、TAC浓度以及骨碱性磷酸酶（BALP）活性。结果。我们发现所有骨肿瘤幸存者与对照组之间血清BALP活性无差异。完成抗癌治疗后的骨肉瘤患者TAC、GSH、GSH/GSSG比值以及GSSG值均显著高于健康受试者。在尤文肉瘤患者中，我们发现其TOC浓度值显著高于健康儿童。此外，尤文肉瘤幸存者的TOC浓度和OSI指数值更高（p < 0.01），但GSH/GSSG比值低于骨肉瘤幸存者（p < 0.05）。在幸存者中观察到TOC与治疗后时间呈正相关。结论。我们发现骨肿瘤幸存者在完成抗癌治疗后，促氧化剂和抗氧化剂之间的平衡仍持续紊乱。此外，TOC值升高以及治疗后时间延长可能提示骨肿瘤幸存者治疗后氧化过程增加。进一步观察将有助于评估氧化剂/抗氧化剂状态与幸存者骨肿瘤疾病复发易感性之间的关系。
